GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Deferred Tax

HMTXF (Hemostemix) Deferred Tax : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Hemostemix Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Hemostemix's change in deferred tax for the three months ended in Dec. 2024 was $0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Hemostemix Deferred Tax Historical Data

The historical data trend for Hemostemix's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemostemix Deferred Tax Chart

Hemostemix Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Deferred Tax
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.20 0.36 - -

Hemostemix Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Hemostemix Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hemostemix Deferred Tax Related Terms

Thank you for viewing the detailed overview of Hemostemix's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemostemix Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemostemix Inc (OTCPK:HMTXF) » Definitions » Deferred Tax
Comparable Companies
XCNQ:PREV XCNQ:BETR TSX:CSCI XCNQ:TELI TSXV:KNE XCNQ:BIOV XCNQ:MDMA TSX:RVX TSXV:SBM TSXV:CYTO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
2VF0:Germany HEM:Canada
Address
707 - 7th Avenue SouthWest, Suite 1150, Calgary, AB, CAN, T2P 3H6
Website
https://www.hemostemix.com
Hemostemix Inc is a biotechnology company. The company's principal business activity is developing, manufacturing, and commercializing blood-derived cell therapies for medical conditions. The Company's technology is a platform for developing autologous cell therapies to treat vascular diseases. The Company's clinical stage consists of ACP-01, autologous cell therapy for the treatment of critical limb ischemia.